Get the Stockscreener App
0.6299
4.08%
-0.0268
After Hours:
.62
-0.0099
-1.57%
Hcw Biologics Inc stock is traded at $0.6299, with a volume of 33,309.
It is down -4.08% in the last 24 hours and down -36.37% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$0.6567
Open:
$0.6567
24h Volume:
33,309
Relative Volume:
0.36
Market Cap:
$3.63M
Revenue:
$832.80K
Net Income/Loss:
$-21.55M
P/E Ratio:
-0.0523
EPS:
-12.0465
Net Cash Flow:
$-12.71M
1W Performance:
+14.61%
1M Performance:
-36.37%
6M Performance:
-85.14%
1Y Performance:
-95.35%
1-Day Range:
$0.58
$0.6604
1-Week Range:
$0.4859
$0.7802
52-Week Range:
$0.4859
$17.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.6299 | 3.78M | 832.80K | -21.55M | -12.71M | -12.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics (NASDAQ: HCWB) seeks warrant approvals at Apr 27 meeting - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HCW Biologics regains compliance with all continued listing rules for Nasdaq per Nasdaq determination letter - marketscreener.com
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight - TipRanks
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - The Manila Times
HCW Biologics (NASDAQ: HCWB) back in full Nasdaq compliance - Stock Titan
HCW Biologics : February 2026 - marketscreener.com
EV Market: Is HCW Biologics Inc gaining market shareJuly 2025 Sector Moves & Stock Timing and Entry Methods - baoquankhu1.vn
EDGAR Filing Documents for 0000950170-24-127198 - SEC.gov
HCW Biologics Completes Follow-On Offering to Fund Pipeline - TipRanks
HCW Biologics Prices $1.5 Million Follow-On Offering of 2.48M Units at $0.6055 - TradingView
HCW Biologics Prices $1.5 Million Unit Offering - marketscreener.com
HCW Biologics lines up $1.5M, cuts warrant price to $0.6055 - Stock Titan
HCW Biologics Announces Follow-On Offering Pricing - Intellectia AI
HCW Biologics Inc. Announces Pricing of Follow-On Offering to Fund Immunotherapy Development - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - marketscreener.com
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire Inc.
Chipmakers Recap: Will HCW Biologics Inc outperform tech stocksJuly 2025 Update & Expert-Curated Trade Recommendations - baoquankhu1.vn
HCWB PE Ratio & Valuation, Is HCWB Overvalued - Intellectia AI
HCW Biologics Licenses TRBC Asset to China JV Trimmune - TipRanks
HCW Biologics enters $7 million licensing deal with China-based Trimmune - Investing.com Nigeria
HCW Biologics and WY Biotech announce closing of first round of financing for newly formed joint venture Trimmune - marketscreener.com
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - Investing News Network
Hcw Biologics And Wy Biotech Announce Closing Of First Round Of Financing For Newly Formed Joint Venture Trimmune - TradingView
Inside HCW Biologics’ $7M deal to test a new cancer drug in China - Stock Titan
Is HCW Biologics Inc. forming a breakout patternJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - mfd.ru
What is HCW Biologics Inc.’s book value per shareWeekly Investment Recap & Technical Pattern Based Buy Signals - mfd.ru
Downgrade Watch: How sensitive is HCW Biologics Inc to inflationFed Meeting & Weekly Setup with ROI Potential - baoquankhu1.vn
Market Leaders: Can HCW Biologics Inc. stock double in the next yearJuly 2025 PreEarnings & Low Volatility Stock Suggestions - baoquankhu1.vn
RSI Check: What is the earnings history of HCW Biologics IncJuly 2025 Earnings & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Risk Off: Can HCW Biologics Inc stock double in the next yearPortfolio Value Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
HCW Biologics restructures obligations to regain Nasdaq compliance - MSN
US Stocks Recap: Is HCW Biologics Inc. forming a breakout patternJuly 2025 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Is HCW Biologics Inc. stock recession proofEarnings Recap Summary & Weekly Sector Rotation Insights - Улправда
How analysts rate HCW Biologics Inc. stock todayQuarterly Trade Summary & AI Enhanced Execution Alerts - ulpravda.ru
Will HCW Biologics Inc. stock attract ESG investorsJuly 2025 Spike Watch & Safe Capital Preservation Plans - Улправда
HCW Biologics Restructures Obligations to Regain Nasdaq Compliance - The Globe and Mail
HCW Biologics reports steps to regain Nasdaq compliance following equity transactions - Investing.com Nigeria
HCW Biologics reports steps to regain Nasdaq compliance following equity transactions By Investing.com - Investing.com South Africa
HCW Biologics Achieves Nasdaq Compliance Milestone - TradingView — Track All Markets
Returns Recap: Will HCW Biologics Inc stock attract ESG investorsEarnings Beat & Daily Price Action Insights - moha.gov.vn
HCW Biologics Granted Nasdaq Compliance Extension - MSN
Aug Analyst Calls: Is HCW Biologics Inc stock recession proofGDP Growth & AI Enhanced Trade Execution Alerts - Bộ Nội Vụ
US Market Recap: How analysts rate HCW Biologics Inc stock todayWeekly Investment Summary & Precise Buy Zone Identification - Bộ Nội Vụ
HCW Biologics (NASDAQ:HCWB) Shares Down 0.2% – Time to Sell? - Defense World
Reviewing HCW Biologics (NASDAQ:HCWB) and ImmunityBio (NASDAQ:IBRX) - Defense World
HCW Biologics Earnings Notes - Trefis
Is HCW Biologics Inc. stock gaining market shareJuly 2025 Opening Moves & Verified Momentum Stock Ideas - Улправда
Is HCW Biologics Inc. stock attractive for growth ETFsMarket Performance Report & Low Drawdown Investment Ideas - Улправда
Is HCW Biologics Inc. stock a buy in volatile markets2025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Can HCW Biologics Inc. stock deliver consistent earnings growthMarket Activity Summary & AI Forecasted Entry/Exit Points - DonanımHaber
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):